Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q00325
UPID:
S25A3_HUMAN
Alternative names:
Phosphate carrier protein, mitochondrial; Phosphate transport protein
Alternative UPACC:
Q00325; B3KS34; Q7Z7N7; Q96A03
Background:
The Solute Carrier Family 25 Member 3, also known as the Phosphate Carrier Protein, mitochondrial, plays a crucial role in transporting phosphate or copper ions across the mitochondrial inner membrane. It is essential for mitochondrial oxidative phosphorylation, which converts ADP to ATP, and for maintaining the mitochondrial matrix copper pool necessary for cytochrome C oxidase complex assembly.
Therapeutic significance:
Mitochondrial phosphate carrier deficiency, a disorder linked to this protein, is characterized by lactic acidosis, hypertrophic cardiomyopathy, and muscular hypotonia, leading to early mortality. Understanding the role of Solute Carrier Family 25 Member 3 could open doors to potential therapeutic strategies for this and related mitochondrial disorders.